STERIS completes acquisition of synergy health
November 4, 2015
STERIS plc (NYSE: STE) ("STERIS") announced today that it has completed the previously announced combination of STERIS Corporation and Synergy Health plc ("Synergy"). As a result of the transaction, STERIS Corporation and Synergy are now combined under STERIS. The ordinary shares of STERIS will begin trading on the New York Stock Exchange under STERIS Corporation's historical ticker symbol, "STE" beginning tomorrow, November 3, 2015.
"This combination marks a significant milestone for STERIS, creating a stronger global leader in infection prevention and sterilization, better-positioned to provide comprehensive solutions to medical device companies, pharmaceutical companies, hospitals and other healthcare facilities around the world," said Walt Rosebrough, President and CEO of STERIS.
On Friday, October 30, 2015 the U.S. Federal Trade Commission ("FTC") announced that it has decided to not pursue further administrative proceedings challenging the combination between STERIS Corporation and Synergy, and the FTC has formally dismissed the administrative complaint.
Lazard acted as financial advisor and Wachtell, Lipton, Rosen & Katz and Jones Day acted as legal advisors to STERIS in connection with the combination. Investec Bank plc acted as financial advisor and DLA Piper acted as legal counsel for Synergy.
STERIS's mission is to help our Customers create a healthier and safer world by providing innovative healthcare and life science product and service solutions around the globe. For more information, visit www.steris.com
"This combination marks a significant milestone for STERIS, creating a stronger global leader in infection prevention and sterilization, better-positioned to provide comprehensive solutions to medical device companies, pharmaceutical companies, hospitals and other healthcare facilities around the world," said Walt Rosebrough, President and CEO of STERIS.
On Friday, October 30, 2015 the U.S. Federal Trade Commission ("FTC") announced that it has decided to not pursue further administrative proceedings challenging the combination between STERIS Corporation and Synergy, and the FTC has formally dismissed the administrative complaint.
Lazard acted as financial advisor and Wachtell, Lipton, Rosen & Katz and Jones Day acted as legal advisors to STERIS in connection with the combination. Investec Bank plc acted as financial advisor and DLA Piper acted as legal counsel for Synergy.
About STERIS
STERIS's mission is to help our Customers create a healthier and safer world by providing innovative healthcare and life science product and service solutions around the globe. For more information, visit www.steris.com
About STERIS
STERIS is a leading global provider of products and services that support patient care with an emphasis on infection prevention. WE HELP OUR CUSTOMERS CREATE A HEALTHIER AND SAFER WORLD by providing innovative healthcare and life sciences products and services. For more information, visit www.steris.com.
Related Posts
